Johnson & Johnson (JNJ) — closed signal from November 9, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on February 7, 2026.
Predicted vs. what happened
What happened
Reached its target in 12 days.
The thesis — published November 9, 2025
Johnson & Johnson's share price looks beaten down after a sharp slide, which often sets up a short-term rebound. Investor interest remains solid and the stock is easy to trade. A new FDA approval for DARZALEX Faspro in high risk smoldering multiple myeloma adds timely good news that can help. If the price can climb back above about $190 and hold, it may start a steadier recovery. Ongoing lawsuits and insurance pressures are risks.
Primary drivers
- Sharp recent drop hints at a near-term bounce as fear appears overdone
- New FDA approval for DARZALEX Faspro could lift demand in the near term
- Healthcare name with steadier demand even when the economy slows
- Active trading and steady investor interest support price stability
How it played out
JNJ: target reached in 12 days
Lyra published JNJ at $185.39 on 2025-11-09 with 10% expected growth and a $202.65 target. The thesis pointed to a sharp recent drop, a possible short-term rebound, solid investor interest, easy trading, steadier healthcare demand, and a new FDA approval for DARZALEX Faspro. It also said a move back above about $190 could help a steadier recovery.
Inside the window, JNJ reached the target in 12 days. The stock later peaked at $240.94 on 2026-02-06, with a 30% peak gain, and ended at $239.99. The published thesis played out. The move went beyond the target before the window closed.
What happened during the window
On January 21, 2026, Johnson & Johnson reported fourth-quarter 2025 sales of $24.6 billion, up 9.1%, and full-year 2025 sales of $94.2 billion, up 6.0%. The same release said the company issued 2026 guidance of $100.5 billion in estimated reported sales and adjusted EPS of $11.53.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.